跳至主要内容
临床试验/NCT04686487
NCT04686487已完成不适用

Stereotactic Ablative Radiotherapy in Patients With Hypertrophic Obstructive Cardiomyopathy: First in Man Pilot Study

Second Xiangya Hospital of Central South University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2021年1月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
5
试验地点
1
主要终点
Safety of stereotactic ablative radiotherapy

研究概览

简要总结

Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiting the heart with increasing risk of sudden cardiac death, heart failure, and atrial fibrillation. Surgical septal myectomy and alcohol septal ablation are two invasive therapies for drug-refractory symptomatic patients with HOCM. Unfortunately, some patients may be unsuitable for both the two procedures. Recently, stereotactic ablative radiotherapy, usually used for the treatment of tumours, was confirmed to be feasible, safe and effective in destroying abnormal tissue in heart by targeting high energy heavy ion beams at a specific area of the body precisely. In this study we will determine whether radiation ablation, can be used to destroy the thick heart muscle at the point of obstruction safely and effectively.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female aged ≥ 18 years
  • Drug-refractory symptomatic patients with HOCM
  • Willing and able to give written informed consent

排除标准

  • Enrolled in another clinical study.
  • Patient unable to tolerate lying flat for one hour
  • Pregnant Or Lactating Women
  • With other contraindications for receive stereotactic ablative radiotherapy

结局指标

主要结局

Safety of stereotactic ablative radiotherapy

时间窗: 3 months

The primary safety endpoint is defined as serious adverse events (SAEs) that are possibly/probably/definitely related to study treatment, based on previously published data for expected invasive alcohol septal-ablation procedures.

次要结局

  • Assessment of MACE endpoints(1, 3, 6 and 12 months)
  • Development of complete heart block, atrial or ventricular arrhythmias(1, 3, 6 and 12 months)
  • Change in LVOT gradient(1, 3, 6 and 12 months)
  • Change in exercise capacity(1, 3, 6 and 12 months)
  • Change in LV wall thickness(1, 3, 6 and 12 months)

研究者

发起方
Second Xiangya Hospital of Central South University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shenghua Zhou

Professor

Second Xiangya Hospital of Central South University

研究点 (1)

Loading locations...

相似试验